Woodline Partners LP Sells 27,595 Shares of Boston Scientific Co. (NYSE:BSX)

Woodline Partners LP lessened its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 5.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 482,453 shares of the medical equipment provider's stock after selling 27,595 shares during the quarter. Woodline Partners LP's holdings in Boston Scientific were worth $43,093,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Colonial Trust Co SC boosted its position in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 260 shares during the period. TFC Financial Management Inc. boosted its holdings in shares of Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after buying an additional 210 shares during the period. Valley National Advisers Inc. grew its stake in Boston Scientific by 262.4% in the 4th quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 286 shares during the last quarter. Fairway Wealth LLC bought a new position in Boston Scientific in the 4th quarter worth $36,000. Finally, Global Trust Asset Management LLC lifted its position in Boston Scientific by 64.5% during the 4th quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 171 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $106.61 on Tuesday. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.36. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock has a fifty day moving average price of $99.39 and a two-hundred day moving average price of $96.90. The firm has a market capitalization of $157.72 billion, a P/E ratio of 85.29, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm's quarterly revenue was up 20.9% on a year-over-year basis. During the same period last year, the firm posted $0.56 EPS. As a group, analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. The trade was a 14.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 263,163 shares of company stock worth $27,129,540. Insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. StockNews.com raised Boston Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, April 29th. Barclays raised their target price on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC upped their price target on Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Wells Fargo & Company increased their price objective on Boston Scientific from $100.00 to $118.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Finally, Stifel Nicolaus boosted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Twenty-three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $114.74.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.